Table 2.
Histology characteristics and 10x Genomics chemistries for 25 synovial tissue samples from patients with inflammatory arthritis, included in the generation of the single-cell reference map of the fresh human synovium
| Number of biopsies | |
|---|---|
| Protocol | |
| 1: Original, Donlin L. et al.22 | 10 |
| 2: Optimized, Edalat SG. et al. | 15 |
| Sex∗ | |
| Female | 18 |
| Male | 5 |
| Age | |
| Median (range) | 55.5 (20–81) |
| Therapy at biopsy∗∗ | |
| No therapy | 3 |
| Corticosteroid | 1 |
| Corticosteroid + cDMARD | 1 |
| cDMARDs | 2 |
| bDMARDs | 3 |
| cDMARD + bDMARD | 2 |
| cDMARD + JAKi | 3 |
| Corticosteroid + cDMARD + JAKi | 1 |
| Antibiotics | 2 |
| Refractory arthritis∗∗∗ | 6 |
| Krenn synovitis score∗∗∗∗ | |
| Median (range) | 4 (2–9) |
| Pathotype | |
| Diffuse myeloid | 10 |
| Lympho-myeloid | 9 |
| Fibroid | 5 |
| Unclassified | 1 |
| 10x Genomics Chemistry | |
| 3′ v3.0 | 5 |
| 3′ v3.1 | 20 |
See also Figure S1. Numbers denote the biopsies processed. F: female, M: male, DM: diffuse myeloid, LM: lymphoid myeloid, F: fibroid, pauci-immune, U: unclassified. ∗Gender data not reported for 2 patients in protocol 2 cohort, ∗∗The values indicate the number of patients receiving different disease-modifying antirheumatic drugs (DMARDs) at the time of biopsy with data missing for 5 patients. Conventional DMARDs (cDMARDs) included methotrexate, leflunomide, salazopyrin, sulfasalazine and plaquenil. Biological DMARDs (bDMARDs) included anti-TNF, anti-IL-6, anti-IL-17A, anti -IL-12/IL-23 and anti-IL-23 therapies, and therapeutic fusion proteins (soluble TNFa receptor, CTLA4). Janus kinase inhibitors (JAKi) included baricitinib and tofacitinib. Antibiotics included vibramycin and doxycycline. ∗∗∗Indicated is the number of patients failing multiple cDMARDs and bDMARD/JAKi in the period before biopsy data about treatment history are missing for 6 patients. ∗∗∗∗Krenn scoring, based on 21 out of 25 synovial tissues.